Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 828

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Open access
Lebwohl, Mark, Strober, Bruce, Menter, Alan, Gordon, Kenneth, Weglowska, Jolanta, Puig, Lluis, Papp, Kim, Spelman, Lynda, Toth, Darryl, Kerdel, Francisco, Armstrong, April W., Stingl, Georg, Kimball, Alexa B., Bachelez, Herve, Wu, Jashin J., Crowley, Jeffrey, Langley, Richard G., Blicharski, Tomasz, Paul, Carle, Lacour, Jean-Philippe, Tyring, Stephen, Kircik, Leon, Chimenti, Sergio, Callis Duffin, Kristina, Bagel, Jerry, Koo, John, Aras, Gary, Li, Joanne, Song, Wenjie, Milmont, Cassandra E., Shi, Yifei, Erondu, Ngozi, Klekotka, Paul, Kotzin, Brian, Nirula, Ajay·2015·New England Journal of Medicine

Abstract

BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis. METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ≤100 kg and 90 mg for patients >100 kg), or placebo. At week 12, patients receiving brodalumab were randomly assigned again to receive a brodalumab maintenance dose of 210 mg every 2 weeks or 140 mg every 2 weeks, every 4 weeks, or every 8 weeks; patients receiving ustekinumab continued to receive ustekinumab every 12 weeks, and patients receiving placebo received 210 mg of brodalumab every 2 weeks. The primary aims were to evaluate the superiority of brodalumab over placebo at week 12 with respect to at least a 75% reduction in the psoriasis area-and-severity index score (PASI 75) and a static physician's global assessment (sPGA) score of 0 or 1 (clear or almost clear skin), as well as the superiority of brodalumab over ustekinumab at week 12 with respect to a 100% reduction in PASI score (PASI 100). RESULTS: At week 12, the PASI 75 response rates were higher with brodalumab at the 210-mg and 140-mg doses than with placebo (86% and 67%, respectively, vs. 8% [AMAGINE-2] and 85% and 69%, respectively, vs. 6% [AMAGINE-3]; P<0.001); the rates of sPGA scores of 0 or 1 were also higher with brodalumab (P<0.001). The week 12 PASI 100 response rates were significantly higher with 210 mg of brodalumab than with ustekinumab (44% vs. 22% [AMAGINE-2] and 37% vs. 19% [AMAGINE-3], P<0.001). The PASI 100 response rates with 140 mg of brodalumab were 26% in AMAGINE-2 (P=0.08 for the comparison with ustekinumab) and 27% in AMAGINE-3 (P=0.007). Rates of neutropenia were higher with brodalumab and with ustekinumab than with placebo. Mild or moderate candida infections were more frequent with brodalumab than with ustekinumab or placebo. Through week 52, the rates of serious infectious episodes were 1.0 (AMAGINE-2) and 1.3 (AMAGINE-3) per 100 patient-years of exposure to brodalumab. CONCLUSIONS: Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis. (Funded by Amgen; AMAGINE-2 and AMAGINE-3 ClinicalTrials.gov numbers, NCT01708603 and NCT01708629.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1503824

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 828

Metadata

Authors
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., Armstrong, A. W., Stingl, G., Kimball, A. B., Bachelez, H., Wu, J. J., Crowley, J., Langley, R. G., Blicharski, T., Paul, C., Lacour, J.-P., Tyring, S., Kircik, L., Chimenti, S., Callis Duffin, K., Bagel, J., Koo, J., Aras, G., Li, J., Song, W., Milmont, C. E., Shi, Y., Erondu, N., Klekotka, P., Kotzin, B., & Nirula, A.
Venue
New England Journal of Medicine
Published
2015-10
Volume
373
Issue
14
Pages
1318-1328
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2326643498
Cited by
828
References
21
FWCI
36.96
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. https://app.cochat.ai/papers/10.1056/nejmoa1503824
The paper
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., Armstrong, A. W., Stingl, G., Kimball, A. B., Bachelez, H., Wu, J. J., Crowley, J., Langley, R. G., Blicharski, T., Paul, C., . . . Nirula, A. (2015). Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1503824

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.